Literature DB >> 18439818

Management of cancer pain: basic principles and neuropathic cancer pain.

B Laird1, L Colvin, M Fallon.   

Abstract

Pain is one of the commonest symptoms in patients with cancer occurring in as many as 90% of patients during their illness. Pain is a complex phenomenon, which can be exacerbated by numerous other factors. This paper discusses the common strategies for the management of cancer pain in general and also neuropathic cancer pain. Using the World Health Organisation (WHO) analgesic ladder for cancer pain relief, 80% of cancer pain can usually be controlled. It follows therefore that 20% of cancer pain can be difficult to control. Neuropathic cancer pain is often in this category and the use of adjuvant analgesics such as amitriptyline and gabapentin is important. Optimum cancer pain control is achieved by integrating standard analgesic approaches during tumouricidal therapy or any other active cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18439818     DOI: 10.1016/j.ejca.2008.03.022

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  20 in total

1.  The Characteristics and the Pharmacological Management of Cancer Pain and Its Effect on the Patients' Daily Activities and their Quality of Life: A Cross - Sectional study from Malaysia.

Authors:  Bhuvan K C; Zuraidah Binti Mohd Yusoff; Alian A Alrasheedy; Saad Othman
Journal:  J Clin Diagn Res       Date:  2013-07-01

2.  Emerging drugs for cancer-related pain.

Authors:  Sebastiano Mercadante
Journal:  Support Care Cancer       Date:  2011-09-23       Impact factor: 3.603

3.  Prevention and treatment of oral mucositis in patients with head and neck cancer treated with (chemo) radiation: report of an Italian survey.

Authors:  Paolo Bossi; Gianmauro Numico; Vitaliana De Santis; Maria Grazia Ruo Redda; Alessia Reali; Liliana Belgioia; Maria Cossu Rocca; Ester Orlandi; Mario Airoldi; Alamalina Bacigalupo; Marta Mazzer; Gabriella Saibene; Elvio Russi
Journal:  Support Care Cancer       Date:  2014-02-25       Impact factor: 3.603

4.  CT-guided microinvasive intervention in treating refractory carcinous pain.

Authors:  Hui-Cun Cao; Jian Liu; Guang-Shao Cao; Zhen-Yu Wang; Xiao-Yang Zhao; Tian-Xiao Li
Journal:  Int J Clin Exp Med       Date:  2015-04-15

Review 5.  Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants.

Authors:  J K Hicks; J J Swen; C F Thorn; K Sangkuhl; E D Kharasch; V L Ellingrod; T C Skaar; D J Müller; A Gaedigk; J C Stingl
Journal:  Clin Pharmacol Ther       Date:  2013-01-16       Impact factor: 6.875

6.  A randomized, controlled, double-blinded clinical trial of gabapentin 300 versus 900 mg versus placebo for anxiety symptoms in breast cancer survivors.

Authors:  Jill E Lavigne; Charles Heckler; Jennifer L Mathews; Oxana Palesh; Jeffrey J Kirshner; Raymond Lord; Andrew Jacobs; Eric Amos; Gary R Morrow; Karen Mustian
Journal:  Breast Cancer Res Treat       Date:  2012-10-02       Impact factor: 4.872

Review 7.  Acupuncture for cancer pain in adults.

Authors:  Carole A Paley; Mark I Johnson; Osama A Tashani; Anne-Marie Bagnall
Journal:  Cochrane Database Syst Rev       Date:  2015-10-15

8.  A multicentre open-label safety and efficacy study of tetrodotoxin for cancer pain.

Authors:  N A Hagen; B Lapointe; M Ong-Lam; B Dubuc; D Walde; B Gagnon; R Love; R Goel; P Hawley; A Ho Ngoc; P du Souich
Journal:  Curr Oncol       Date:  2011-06       Impact factor: 3.677

9.  Individualized pharmacological treatment of oral mucositis pain in patients with head and neck cancer receiving radiotherapy.

Authors:  Ingrid Stenstrom Ling; Britt Larsson
Journal:  Support Care Cancer       Date:  2010-07-25       Impact factor: 3.603

10.  Z-360, a novel therapeutic agent for pancreatic cancer, prevents up-regulation of ephrin B1 gene expression and phosphorylation of NR2B via suppression of interleukin-1 β production in a cancer-induced pain model in mice.

Authors:  Yuki Orikawa; Hiroki Kato; Koichi Seto; Nobuyoshi Kobayashi; Koji Yoshinaga; Hiroki Hamano; Yuko Hori; Tim Meyer; Mineo Takei
Journal:  Mol Pain       Date:  2010-10-28       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.